ICD-10 Code C20: Malignant neoplasm of rectum

Key Takeaways

ICD-10 Code C20 (Malignant neoplasm of rectum) is a billable ICD-10-CM code valid for 2026 reimbursement, covering primary rectal malignancies including adenocarcinoma, lymphoma, and sarcoma.

C20 carries an Excludes1 note for malignant carcinoid tumor of the rectum (C7A.026), meaning these two codes cannot be reported together on the same claim.

Use C20 for primary rectal cancer only. Secondary (metastatic) malignancy that has spread to the rectum is coded C78.5, not C20 – this distinction is one of the most common coding errors in oncology billing.

Pabau’s claims management software helps oncology and surgical practices attach the correct diagnosis codes, track claim status, and reduce denials tied to miscoded rectal malignancy encounters.

ICD-10 Code C20: Malignant neoplasm of rectum is a billable ICD-10-CM diagnosis code that covers primary rectal malignancies, including adenocarcinoma, lymphoma, and sarcoma. It is valid for 2026 reimbursement.

The guidance below reflects the fiscal year 2026 ICD-10-CM tabular list as maintained by the Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS). Always verify against the current-year release before submitting claims.

C20 definition and billable status

ICD-10 Code C20 is a billable, specific ICD-10-CM diagnosis code. It can be used directly on claims submitted for reimbursement without requiring a more specific subcategory code. C20 is valid for the 2026 fiscal year.

C20 sits within ICD-10-CM Chapter C00-C96, which covers all malignant neoplasms. The subrange C15-C26 groups malignant neoplasms of digestive organs, placing rectal cancer alongside esophageal, gastric, and colon malignancies.

The rectum is the final segment of the large intestine, extending from the sigmoid colon to the anal canal. C20 includes primary malignancies of the rectal ampulla alongside the broader rectal site.

Clinical description: What C20 covers

C20 captures primary malignant neoplasms affecting the rectum. Representative histological types include carcinoma, lymphoma, and sarcoma. In practice, the vast majority of C20 encounters involve adenocarcinoma, which accounts for approximately 95% of rectal malignancies.

The code applies to the following anatomical sites and synonyms documented in the clinical record:

• Malignant neoplasm of rectum (general)
• Malignant neoplasm of rectal ampulla
• Adenocarcinoma of rectum
• Anorectal adenocarcinoma
• Carcinoma of upper rectum
• Rectal carcinoma (when documented as primary)
• Lymphoma of rectum (primary)
• Sarcoma of rectum (primary)

When documentation refers to colorectal cancer without specifying a site, coders must query the treating clinician. C20 is site-specific to the rectum; colorectal cancer involving the colon requires a code from the C18 range instead. Review the full operative or pathology report before assigning C20 to confirm anatomical site.

Excludes1 note for C20

C20 carries a Type 1 Excludes note. Under official ICD-10-CM guidelines, an Excludes1 note means “NOT CODED HERE” – the excluded condition and the code in question represent mutually exclusive diagnoses that cannot occur together.

The single Excludes1 exclusion for C20 is:

• C7A.026 – Malignant carcinoid tumor of the rectum

Carcinoid tumors (neuroendocrine tumors) of the rectum are biologically and histologically distinct from adenocarcinoma and the other malignancies captured by C20. When pathology confirms a carcinoid or neuroendocrine tumor of the rectum, assign C7A.026 – not C20.

Reporting both codes on the same claim will trigger an edit rejection. Under ICD-10-CM rules, the Excludes1 relationship is absolute: no clinical scenario justifies reporting C20 and C7A.026 together.

C20 vs C78.5: primary vs secondary malignant neoplasm of rectum

The most consequential coding decision for rectal malignancy is distinguishing primary from secondary (metastatic) disease. Using the wrong code reverses the clinical picture documented in the record and creates significant billing compliance risk.

When a patient presents with rectal involvement secondary to ovarian cancer, prostate cancer, or another primary, C78.5 is the correct rectal code. The primary-site malignancy code (e.g., C56.x for ovary) is coded first per ICD-10-CM sequencing rules, followed by C78.5.

Assigning C20 in this scenario misrepresents the clinical picture and may trigger payer audits. Reference the CDC/NCHS ICD-10-CM tool to verify current code definitions and tabular notes before submission. The same site-and-morphology specificity governs adjacent digestive-tract malignancy codes.

Documentation requirements for coding rectal cancer ICD-10

Payer audits for oncology codes routinely focus on three documentation elements. Missing any one of them can downgrade a claim or trigger a medical necessity denial.

• Histopathology confirmation. A pathology report documenting malignant histology is the gold standard. The report must specify the tumor site (rectum) and morphology (adenocarcinoma, mucinous adenocarcinoma, lymphoma, etc.).
• Primary site declaration. Clinical documentation must clearly state that the rectum is the primary site – not a metastatic site – to support C20 rather than C78.5. Operative notes, oncology consultation notes, or tumor board summaries are all acceptable sources.
• Staging information. While C20 itself does not have stage-specific subcodes, payers increasingly require staging documentation (TNM or AJCC stage) to authorize high-cost oncology treatments billed alongside C20.

Keeping structured patient records that link pathology reports, oncology notes, and staging documentation to the encounter reduces documentation retrieval time during audits and supports consistent code assignment. Practices handling oncology billing workflows should also review their HIPAA-compliant documentation practices to ensure diagnostic records are stored securely and accessible only to authorized staff.

For queries about site ambiguity or histological subtype, coders should defer to the AAPC’s ICD-10-CM code lookup, which includes index entries, tabular notes, and coding clinic guidance for malignant neoplasms. Using digital clinical forms that capture histological subtype and primary-site confirmation at point of care reduces the need for retrospective documentation queries.

MS-DRG grouping and billing workflow for C20

For inpatient hospital claims, C20 is grouped within Medicare Severity Diagnosis Related Groups (MS-DRG) under the current CMS release. MS-DRG assignment affects facility reimbursement rates and drives case mix index calculations. Coders should confirm the current MS-DRG mapping against the active CMS IPPS rate tables, as grouper versions update annually with each fiscal year release.

On the professional fee side, C20 is commonly paired with the following CPT procedure codes:

• 45190, 45395, 45400 – Rectal excision and proctectomy procedures
• 45171, 45172 – Excision of rectal tumor, transanal approach
• 96401-96417 – Chemotherapy administration codes
• 77301, 77385, 77386 – Radiation oncology planning and delivery
• 45378, 45380 – Colonoscopy with or without biopsy (staging workup)
• 99213-99215 – Established patient office visits (ongoing oncology management)

Medical necessity for surgical and chemotherapy services billed alongside C20 requires the diagnosis to be supported by pathology-confirmed documentation. Payers will expect C20 to appear on claims for colorectal resection, chemotherapy infusion, and radiation services. If C20 is absent from the claim or is replaced by C78.5 on a primary case, medical necessity for definitive surgical treatment may be challenged.

Diagnostic workup often begins with a screening or surveillance colonoscopy, such as screening colonoscopy (G0121) or colonoscopy with polypectomy (45385), before a rectal primary is confirmed and C20 is assigned.

Practices managing oncology encounters can reduce claim errors by using claims management software that validates diagnosis-procedure pairings before submission. Related screening encounters, such as the encounter for screening for malignant neoplasm of the colon (Z12.11), follow their own sequencing rules and should not be conflated with a confirmed C20 diagnosis.

Teams prioritizing patient data security in clinical practice should also verify that oncology diagnosis data is handled under appropriate access controls, given the sensitivity of cancer diagnoses in the patient record.

Reduce ICD-10 claim denials with Pabau

Pabau's claims management tools help oncology and surgical practices attach the correct diagnosis codes, track claim status, and catch C20 vs C78.5 errors before they reach the payer.

Book a demo

Additional related codes for rectal malignancy

Several adjacent codes frequently appear in rectal cancer coding workflows. Knowing when each applies prevents upcoding, downcoding, and Excludes1 violations.

The distinction between C19 (rectosigmoid junction) and C20 (rectum) depends entirely on the tumor’s documented anatomical location. When the treating clinician documents “rectosigmoid tumor” without further specification, query for clarification rather than defaulting to either code.

After curative treatment, surveillance encounters may draw on history codes such as personal history of colonic polyps (Z86.010).

Conclusion

Accurate use of ICD-10 Code C20 requires three things: confirmed primary-site documentation, correct histological subtype identification, and strict application of the Excludes1 note for C7A.026. The C20 vs C78.5 distinction is the single highest-stakes decision in rectal cancer billing – getting it wrong inverts the clinical story and exposes practices to audit risk.

Pabau’s claims management tools help oncology and surgical practices validate diagnosis-procedure pairings at the point of billing, reducing C20-related denials before they reach the payer. To see how Pabau handles oncology coding workflows end to end, book a demo.

Continue your research

Building a HIPAA-compliant oncology documentation workflow? HIPAA compliance for medical offices outlines the documentation controls and access rules that protect sensitive cancer diagnosis records.

Frequently asked questions